MVP Act
Summary
What This Bill Does
The MVP Act codifies value-based purchasing arrangements in the Medicaid drug-rebate statute. A manufacturer may report multiple best-price points for one dosage form and strength only if it offers the arrangement to every state. Manufacturers may still treat an arrangement as a bundled sale.
For average manufacturer price, outcome-triggered refunds, rebates, reimbursements, free goods, or withheld or reduced payments are excluded when a patient fails the arrangement's measures. The rule expressly reaches physician-administered and other drugs not generally dispensed by retail pharmacies. When payment is made in installments, the aggregate contractual price is treated as paid in the first installment for price reporting. HHS must implement these amendments by rule within 180 days.
For Medicare average sales price, the same outcome-triggered remuneration is excluded when the manufacturer elected multiple Medicaid best-price points. Exclusion can keep reported ASP higher than if failed-outcome refunds reduced it, potentially increasing Part B reimbursement and beneficiary coinsurance while supporting manufacturer willingness to offer performance guarantees.
Within 180 days, HHS must guide state Medicaid agencies on value-based arrangements for separately reimbursed inpatient drugs and biologics. Guidance must cover agreements among states and manufacturers, including fund transfers so a patient treated out of state can be treated financially as a resident of the home state.
The bill exempts manufacturer remuneration paid to a state after a patient fails agreed outcomes from the federal antikickback prohibition, with OIG rulemaking within 180 days. GAO must study access, outcomes, patient and system costs, rare-disease therapies, socioeconomic disparities, Medicaid, 340B, Medicare Part B, state spending, pricing in nonparticipating states, pricing structures, and long-term savings, and report by June 30, 2029.
The bill does not require a state or manufacturer to enter an arrangement, guarantee patient access, appropriate implementation funds, set an outcome metric, force a manufacturer to offer commercial terms to Medicaid, or change FDA approval standards.
Who Benefits and How
Medicaid patients, especially those needing expensive gene or rare-disease therapies, may gain access where payment follows outcomes. States receive nationwide offer rights and tools for cross-state treatment. Manufacturers gain price-reporting certainty and an antikickback safe harbor. Hospitals and specialty providers may gain more workable inpatient financing.
Who Bears the Burden and How
Manufacturers must offer a multiple-price arrangement to all states and administer patient outcomes. State Medicaid agencies, CMS, OIG, providers, and data vendors face complex tracking, fund transfers, and reporting. Medicare and beneficiaries may pay more when outcome refunds are excluded from ASP. 340B entities and nonparticipating states face uncertain price interactions.
Key Provisions
- Allows multiple Medicaid best-price points.
- Requires offers to all states.
- Preserves bundled-sale treatment.
- Excludes failed-outcome remuneration from average manufacturer price.
- Treats installment aggregate price as paid initially.
- Requires HHS rulemaking within 180 days.
- Excludes specified remuneration from Medicare ASP.
- Directs guidance for separately paid inpatient drugs.
- Supports interstate Medicaid fund transfers.
- Creates an antikickback exception for state remuneration.
- Requires OIG rulemaking within 180 days.
- Requires a GAO study of access and outcomes.
- Requires analysis of Medicaid, 340B, and Medicare effects.
- Requires analysis of disparities and rare-disease therapies.
- Requires a GAO report by June 30, 2029.
- Creates no mandatory arrangement or product approval.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Codifies Medicaid value-based drug purchasing with optional multiple best-price points offered to every state, coordinates outcome-triggered remuneration and installment pricing with Medicaid and Medicare price reporting, guides interstate inpatient arrangements, creates an antikickback exception, and requires a GAO access, outcomes, cost, and disparity study by June 2029.
Key Policy Areas
Medicaid Drug Rebates, Value-Based Purchasing, Medicare Average Sales Price, Antikickback Law, Rare Disease Therapies
Primary Purpose
Codifies Medicaid value-based drug purchasing with optional multiple best-price points offered to every state, coordinates outcome-triggered remuneration and installment pricing with Medicaid and Medicare price reporting, guides interstate inpatient arrangements, creates an antikickback exception, and requires a GAO access, outcomes, cost, and disparity study by June 2029.
Policy Domains
Sections 2 through 6 multiple best prices, outcome remuneration, installment reporting, Medicare ASP coordination, inpatient guidance and interstate transfers, antikickback exception, implementing rules, and GAO study
Identified Gains
- Medicaid patients needing transformative therapies
- Rare-disease patients receiving gene therapies
- State Medicaid agencies using value contracts
- Drug manufacturers offering performance guarantees
- Biologic manufacturers using installment payments
- Hospitals administering high-cost inpatient drugs
- Patients receiving drugs outside their home states
Identified Costs
- Manufacturers tracking patient outcomes
- State Medicaid value-purchasing staff
- Centers for Medicare and Medicaid Services
- HHS Inspector General rulemaking staff
- Providers supplying outcome data
- Medicare beneficiaries paying Part B coinsurance
- Medicare Part B program
- Government Accountability Office
Sponsors
Legislative Progress
In CommitteeReferred to the Committee on Energy and Commerce, and in …
Introduced in House
Mr. Guthrie (for himself, Mr. Auchincloss, Mrs. Miller-Meeks, Mr. Joyce …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
340B covered entities, Hospitals administering high-cost inpatient drugs, Hospitals paid through bundled inpatient rates
Positive-direction: Hospitals administering high-cost inpatient drugs, Medicaid patients needing transformative therapies, Medicare patients gaining therapy access, Patients receiving drugs outside their home states, Physician practices administering Part B drugs, Rare-disease patients receiving gene therapies, State Medicaid agencies using value contracts
Negative-direction: 340B covered entities, Medicare beneficiaries paying Part B coinsurance, Medicare claims contractors, State Medicaid compliance officers, State Medicaid value-purchasing staff
Centers for Medicare and Medicaid Services, Congressional healthcare committees, Government Accountability Office
Positive-direction: Congressional healthcare committees
Negative-direction: Centers for Medicare and Medicaid Services, Government Accountability Office, HHS Inspector General rulemaking staff, HHS Medicaid guidance staff, Healthcare fraud prosecutors, Medicaid drug rebate administrators, Medicare Part B program
Biologic manufacturers offering performance guarantees, Biologic manufacturers using installment payments, Drug manufacturers offering inpatient arrangements
Positive-direction: Biologic manufacturers offering performance guarantees, Biologic manufacturers using installment payments, Drug manufacturers offering inpatient arrangements, Drug manufacturers offering performance guarantees
Negative-direction: Drug manufacturers supplying study data, Manufacturers documenting outcome payments, Manufacturers tracking patient outcomes
Interstate Medicaid accounting staff, States declining value-based arrangements
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "state"
- → State Medicaid agency entering an arrangement
- "patient"
- → Medicaid beneficiary receiving a covered therapy
- "provider"
- → Hospital or practitioner administering a covered product
- "secretary"
- → HHS Secretary issuing rules and guidance
- "comptroller"
- → GAO official conducting the required study
- "manufacturer"
- → Drug or biologic manufacturer offering outcome-based terms
- "inspector_general"
- → HHS Inspector General implementing the safe harbor
Note: {'scope_ids': ['medicaid_drug_value_based_purchasing'], 'description': 'Participation remains optional, but multiple best-price reporting requires a nationwide state offer; failed-outcome remuneration is excluded from both Medicaid and conditional Medicare calculations, and the statute supports financing mechanics without defining outcomes or guaranteeing access.'}
Key Definitions
Terms defined in this bill
The arrangement defined in 42 C.F.R. 447.502 or a successor regulation and incorporated into the Medicaid statute.
The requirement that a manufacturer offer a multiple-best-price arrangement to every state.
A refund, rebate, reimbursement, free good, or withheld or reduced payment triggered when a patient does not meet contractual outcomes.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology